IGF2 and Wilms tumor: A loss of heterozygosity (i.e., loss of the maternal allele) or loss of imprinting at the H19/IGF2:IG-DMR (i.e., biallelic expression of IGF2) in Wilms’ tumors was subsequently demonstrated by several teams [139,140].